[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100543224":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":17,"responsibleParty":83,"collaborators":7,"id":85,"slug":86,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":87,"sex":93,"minAge":94,"maxAge":7,"enrollmentInfo":95,"targetDuration":98,"studyType":99,"phases":7,"briefSummary":100,"conditions":101,"keywords":108,"overallStatus":33,"whyStopped":7,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"Pfizer","INDUSTRY",null,[9],{"name":10,"affiliation":5,"role":11},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[13],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","1-800-718-1021","ClinicalTrials.gov_Inquiries@pfizer.com",[18,31,38,47,56,62,68,74],{"facility":19,"status":20,"city":21,"state":7,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":7},"Kaohsiung Medical University Hospital","NOT_YET_RECRUITING","Kaohsiung City","807377","Taiwan","TW",{"type":26,"coordinates":27},"Point",[28,29],120.31333,22.61626,{"lat":29,"lon":28},{"facility":32,"status":33,"city":21,"state":7,"zip":34,"country":23,"countryCode":24,"cosmosGeoPoint":35,"geoPoint":37,"contacts":7},"Chang Gung Memorial Hospital at Kaohsiung","RECRUITING","83301",{"type":26,"coordinates":36},[28,29],{"lat":29,"lon":28},{"facility":39,"status":20,"city":40,"state":7,"zip":41,"country":23,"countryCode":24,"cosmosGeoPoint":42,"geoPoint":46,"contacts":7},"Taipei Medical University - Shuang Ho Hospital","New Taipei City","23561",{"type":26,"coordinates":43},[44,45],121.45703,25.06199,{"lat":45,"lon":44},{"facility":48,"status":33,"city":49,"state":7,"zip":50,"country":23,"countryCode":24,"cosmosGeoPoint":51,"geoPoint":55,"contacts":7},"NTUH","Taipei","100",{"type":26,"coordinates":52},[53,54],121.52639,25.05306,{"lat":54,"lon":53},{"facility":57,"status":20,"city":49,"state":7,"zip":58,"country":23,"countryCode":24,"cosmosGeoPoint":59,"geoPoint":61,"contacts":7},"MacKay Memorial Hospital","10449",{"type":26,"coordinates":60},[53,54],{"lat":54,"lon":53},{"facility":63,"status":20,"city":49,"state":7,"zip":64,"country":23,"countryCode":24,"cosmosGeoPoint":65,"geoPoint":67,"contacts":7},"Taipei Veterans General Hospital","11217",{"type":26,"coordinates":66},[53,54],{"lat":54,"lon":53},{"facility":69,"status":20,"city":49,"state":7,"zip":70,"country":23,"countryCode":24,"cosmosGeoPoint":71,"geoPoint":73,"contacts":7},"Tri-Service General Hospital","11490, R.O.C.",{"type":26,"coordinates":72},[53,54],{"lat":54,"lon":53},{"facility":75,"status":20,"city":76,"state":7,"zip":77,"country":23,"countryCode":24,"cosmosGeoPoint":78,"geoPoint":82,"contacts":7},"Chang Gung Hospital Linkou","Taoyuan","333",{"type":26,"coordinates":79},[80,81],121.29696,24.99368,{"lat":81,"lon":80},{"type":84,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100543224","abrocitinib-taiwan-treatment-pattern-and-real-world-study-in-atopic-dermatitis-attract-registry-100543224",false,"NCT06353087","Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)","The Real-world Treatment Patterns and Clinical Outcomes in Moderate-to-severe Atopic Dermatitis (AD) Patients Receiving Abrocitinib","ATTRACT","Inclusion Criteria:\n\nPatients must meet all of the following inclusion criteria to be eligible for inclusion in the study:\n\n1. Patients aged ≥12 years\n2. Patients with confirmed diagnosis of moderate-to-severe AD as assessed by the physician\n3. Patients for whom the physician's decision has been made to newly prescribe abrocitinib in usual clinical practice conditions\n4. Evidence of a personally signed and dated informed consent\u002Fassent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria will not be included in the study:\n\n1. Any prior use of abrocitinib\n2. Simultaneous participation in a study that includes administration of any investigational drug or procedure","ALL","12 Years",{"count":96,"type":97},200,"ESTIMATED","12 Months","OBSERVATIONAL","This study is to describe the real-world treatment patterns and clinical outcomes in moderate-to-severe AD patients receiving abrocitinib over a 12-month observation period, and to describe patient demographic and baseline characteristics.",[102,103,104,105,106,107],"Dermatitis, Atopic","Dermatitis","Eczema","Skin Diseases","Immune System Diseases","Janus Kinase Inhibitors",[109,110,111,112,113,23],"Atopic Dermatitis","Abrocitinib","JAK inhibitors","Real world","Registry","2025-09-02",{"date":116,"type":117},"2025-09-03","ACTUAL",{"date":119,"type":117},"2024-07-01",{"date":121,"type":97},"2026-05-15",{"name":5,"class":6},8]